Lundbeck Gains Amid Speculation of Antidepressant Success

H. Lundbeck A/S, the second-biggest Nordic drug company, rose to its highest price in nine months in Copenhagen on speculation its new treatment for depression will succeed in replacing Lexapro.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.